Cargando…

Multiple gene aberrations and breast cancer: lessons from super-responders

BACKGROUND: The presence of multiple molecular aberrations in patients with breast cancer may correlate with worse outcomes. CASE PRESENTATIONS: We performed in-depth molecular analysis of patients with estrogen receptor-positive, HER2-negative, hormone therapy-refractory breast cancer, who achieved...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wheler, Jennifer J., Atkins, Johnique T., Janku, Filip, Moulder, Stacy L., Yelensky, Roman, Stephens, Philip J., Kurzrock, Razelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446801/ https://www.ncbi.nlm.nih.gov/pubmed/26021831 http://dx.doi.org/10.1186/s12885-015-1439-y

Ejemplares similares

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016)

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
por: Wheler, Jennifer J., et al.
Publicado: (2014)

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms
por: Wheler, Jennifer J., et al.
Publicado: (2014)

Challenges and perspective of drug repurposing strategies in early phase clinical trials
por: Kato, Shumei, et al.
Publicado: (2015)

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance
por: Wheler, Jennifer, et al.
Publicado: (2015)

Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses
por: Wheler, Jennifer, et al.
Publicado: (2013)

A pilot study of temsirolimus and body composition
por: Veasey-Rodrigues, Heloisa, et al.
Publicado: (2013)

PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes
por: Janku, Filip, et al.
Publicado: (2012)

Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening
por: Adashek, Jacob J., et al.
Publicado: (2021)

Androgen receptors beyond prostate cancer: an old marker as a new target
por: Munoz, Javier, et al.
Publicado: (2014)

A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R): Implications for Inhibition of the IGF-1R signal
por: Janku, Filip, et al.
Publicado: (2013)

Castleman’s disease and sarcoidosis, a rare association resulting in a “mixed” response: a case report
por: Mohammed, Anwarullah, et al.
Publicado: (2015)

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience
por: Hou, Ming-Mo, et al.
Publicado: (2014)

KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors
por: Garrido-Laguna, Ignacio, et al.
Publicado: (2012)

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
por: Jardim, Denis L. Fontes, et al.
Publicado: (2014)

P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy
por: Said, Rabih, et al.
Publicado: (2013)

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
por: Falchook, Gerald S., et al.
Publicado: (2014)

Characteristics and survival of patients with advanced cancer and p53 mutations
por: Said, Rabih, et al.
Publicado: (2014)

Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population
por: Wheler, Jennifer, et al.
Publicado: (2013)

Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing
por: Janku, Filip, et al.
Publicado: (2014)

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine
por: Tsimberidou, Apostolia-Maria, et al.
Publicado: (2019)

ALK fusions in the pan-cancer setting: another tumor-agnostic target?
por: Shreenivas, Aditya, et al.
Publicado: (2023)

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology
por: Jardim, Denis L., et al.
Publicado: (2018)

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors
por: Naing, Aung, et al.
Publicado: (2013)

Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer
por: Tsigelny, Igor F., et al.
Publicado: (2015)

Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials
por: Subbiah, Ishwaria M., et al.
Publicado: (2013)

Dosing targeted and cytotoxic two‐drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013
por: Nikanjam, Mina, et al.
Publicado: (2016)

BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes
por: El-Osta, Hazem, et al.
Publicado: (2011)

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab
por: Falchook, Gerald S, et al.
Publicado: (2014)

Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials
por: Said, Rabih, et al.
Publicado: (2014)

A framework for genomic biomarker actionability and its use in clinical decision making
por: Vidwans, Smruti J., et al.
Publicado: (2014)

Novel Secondary Somatic Mutations in Ewing's Sarcoma and Desmoplastic Small Round Cell Tumors
por: Jiang, Yunyun, et al.
Publicado: (2014)

Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The university of Texas MD Anderson cancer center experience
por: Corrales-Medina, Fernando F., et al.
Publicado: (2014)

PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
por: Janku, Filip, et al.
Publicado: (2011)

Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders
por: Ashina, Sait, et al.
Publicado: (2023)

Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications
por: Cohen, Philip R., et al.
Publicado: (2015)

Cutaneous Metastatic Cancer: Carcinoma Hemorrhagiectoides Presenting as the Shield Sign
por: Cohen, Philip R, et al.
Publicado: (2021)

Nailing the Diagnosis: Onychotillomania in Patients With Artificial Nails—An Underrecognized Phenomenon?
por: Cohen, Philip R, et al.
Publicado: (2022)

Dermatologic Disease-Directed Targeted Therapy (D(3)T(2)): The Application of Biomarker-Based Precision Medicine for the Personalized Treatment of Skin Conditions—Precision Dermatology
por: Cohen, Philip R., et al.
Publicado: (2022)

Germline Testing of Mismatch Repair Genes Is Needed in the Initial Evaluation of Patients With Muir-Torre Syndrome-Associated Cutaneous Sebaceous Neoplasms: A Case Series
por: Cohen, Philip R, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8g21imj11hd5mc9gpdrla5ic44